UY25051A1 - Composiciones para el tratamiento de diabetes mellitus - Google Patents

Composiciones para el tratamiento de diabetes mellitus

Info

Publication number
UY25051A1
UY25051A1 UY25051A UY25051A UY25051A1 UY 25051 A1 UY25051 A1 UY 25051A1 UY 25051 A UY25051 A UY 25051A UY 25051 A UY25051 A UY 25051A UY 25051 A1 UY25051 A1 UY 25051A1
Authority
UY
Uruguay
Prior art keywords
diabetes mellitus
treatment
compositions
alpha
insulin sensitizer
Prior art date
Application number
UY25051A
Other languages
English (en)
Inventor
Stephen Alistair Dr Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY25051A1 publication Critical patent/UY25051A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

La presente invención se refiere al uso de un sensibilizador a insulina y un agente antihiperglucémico inhibidor de la alfa-glucosidasa para la fabricación de medicamentos útiles en el tratamiento de la diabetes mellitus y condiciones asociadas con diabetes mellitus en un mamífero. Se caracteriza porque el sensibilizador a insulina es una cantidad entre 2 a 12 mg de compuesto 5-(4-(2-(N-metil-N-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona; y el agente antihiperglucémico inhibidor de alfa-glucosidasa es acarbosa, emiglitato o miglitol.
UY25051A 1997-06-18 1998-06-18 Composiciones para el tratamiento de diabetes mellitus UY25051A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
UY25051A1 true UY25051A1 (es) 2000-09-29

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25051A UY25051A1 (es) 1997-06-18 1998-06-18 Composiciones para el tratamiento de diabetes mellitus

Country Status (24)

Country Link
EP (1) EP0975343A1 (es)
JP (1) JP2001523271A (es)
KR (1) KR20010013845A (es)
CN (1) CN1274282A (es)
AP (1) AP9901720A0 (es)
AR (2) AR013352A1 (es)
AU (1) AU8799998A (es)
BG (1) BG103966A (es)
BR (1) BR9810186A (es)
CA (1) CA2294134A1 (es)
CO (1) CO4940453A1 (es)
DZ (1) DZ2519A1 (es)
EA (1) EA200000040A1 (es)
IL (1) IL133138A0 (es)
MA (1) MA26510A1 (es)
NO (1) NO996270L (es)
NZ (1) NZ501345A (es)
OA (1) OA11631A (es)
PE (1) PE89199A1 (es)
PL (1) PL337577A1 (es)
SK (1) SK179499A3 (es)
TR (1) TR199903072T2 (es)
UY (1) UY25051A1 (es)
WO (1) WO1998057635A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AU8799998A (en) 1999-01-04
WO1998057635A1 (en) 1998-12-23
AR014881A1 (es) 2001-04-11
JP2001523271A (ja) 2001-11-20
IL133138A0 (en) 2001-03-19
BR9810186A (pt) 2000-08-08
EP0975343A1 (en) 2000-02-02
CN1274282A (zh) 2000-11-22
MA26510A1 (fr) 2004-12-20
PE89199A1 (es) 1999-10-23
NO996270D0 (no) 1999-12-17
NO996270L (no) 1999-12-17
CA2294134A1 (en) 1998-12-23
AR013352A1 (es) 2000-12-27
OA11631A (en) 2004-11-22
BG103966A (bg) 2000-07-31
KR20010013845A (ko) 2001-02-26
TR199903072T2 (xx) 2000-07-21
NZ501345A (en) 2001-10-26
PL337577A1 (en) 2000-08-28
CO4940453A1 (es) 2000-07-24
AP9901720A0 (en) 1999-12-31
SK179499A3 (en) 2000-11-07
DZ2519A1 (fr) 2003-02-01
EA200000040A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
UY25049A1 (es) Composiciones para tratamiento para diabetes mellitus
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
UY25102A1 (es) Nueva composición para el tratamiento de diabetes mellitus
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
EA200601144A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AR045230A1 (es) Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2- piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona y otro agente antidiabetico adicional; procedimiento para su preparacion y uso de 5-[4-[2-(metil-n-(2-piridil)-amino)-etoxi]- bencil]- tiazolidino-2,4-diona y otro agente antidiabetic
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
UY25101A1 (es) Método para el tratamiento de la diabetes mellitus y las condiciones asociadas
EA200101102A1 (ru) Новый фармацевтический препарат
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
HUP0301799A2 (hu) 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxo-tiazolidin-hidrojodid alkalmazása diabetetes mellitus kezelésére, eljárás a vegyület előállítására és ezt tartalmazó gyógyszerkészítmény
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
EA200300232A1 (ru) Тартратные соли производного тиазолидиндиона
CO5150180A1 (es) Nueva composicion y uso liberacion modificada
TH36758A (th) กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน
ECSP003434A (es) Nuevos compuestos

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20121204